ANRO Stock Forecast & Price Target

Alto Neuroscience is attractive because its lead asset ALTO-207 is supported by independent pramipexole data, including a large placebo-adjusted effect in TRD and a Nature Medicine result showing anhedonia improvement, which strengthens confidence in the Phase 2b PACE-1 readout expected in 2H27. The company’s three-trial PACE program—PACE-1, PACE-2, and PACE-3—could broaden the label from adjunctive use into monotherapy, expand the addressable TRD population, and accelerate the path to a potential NDA, while ALTO-300 and ALTO-100 provide additional biomarker-based readouts in 1H27 and mid-2027. Financially, approximately $338 million of pro forma cash and runway through 2030 reduce near-term funding pressure, giving management room to execute across multiple catalysts and supporting a more favorable long-term outlook.

Alto Neuroscience is facing a difficult fundamental setup because the commercial case for ALTO-207 still depends on proving that a generic pramipexole/ondansetron combination can overcome low real-world dosing, slow titration, and payer resistance to separate generic pills. Its earlier ALTO-100 Phase 2b trial missed the primary endpoint, and the cited subgroup signals from adjunctive patients do not establish efficacy, while the company has since tightened biomarker and adherence requirements to reduce the risk of similar execution issues. Financially, spending is rising sharply as R&D reached $22.1 million in 2Q26 versus $13.1 million in 2Q25, net loss widened to $27.6 million, and expected annual equity raises of $150 million to $200 million in 2027E–2029E imply meaningful dilution risk.